The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Targeting natural killer cells in cancer immunotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedFunctions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Innate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2013) · Nature Reviews Immunology · doi:10.1038/nri3365 · Cited by 2,389
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
Besse, B., Charrier, M., Lapierre, V., Dansin, E., Lantz, O., Planchard, D., Le Chevalier, T., Livartoski, A., Barlesi, F., Laplanche, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1071008 · Cited by 749
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3329 · Cited by 711
TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
Viel, S., Marçais, A., Guimaraes, F. S.-F., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aad1884 · Cited by 672
Self-citationRubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Marçais, A., Cherfils-Vicini, J., Viant, C., Degouve, S., Viel, S., Fenis, A., Rabilloud, J., Mayol, K., Tavares, A., Bienvenu, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2936 · Cited by 614
Self-tolerance of natural killer cells
Raulet, D. H., & Vance, R. E. (2006) · Nature Reviews Immunology · doi:10.1038/nri1863 · Cited by 608
NKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599
Perforin-mediated target-cell death and immune homeostasis
Voskoboinik, I., Smyth, M. J., & Trapani, J. A. (2006) · Nature reviews. Immunology · doi:10.1038/nri1983 · Cited by 592
Self-citationRomee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M. T., Town, L., Ritchie, D. S., Colonna, M., Andrews, D. M., & Smyth, M. J. (2014) · Nature Immunology · doi:10.1038/ni.2850 · Cited by 492
Self-citationBalancing natural killer cell activation through paired receptors
Martinet, L., & Smyth, M. J. (2015) · Nature Reviews Immunology · doi:10.1038/nri3799 · Cited by 485
Self-citationParkhurst, M. R., Riley, J. P., Dudley, M. E., & Rosenberg, S. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1347 · Cited by 475
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Developmental pathways that generate natural-killer-cell diversity in mice and humans
Huntington, N. D., Vosshenrich, C. A. J., & Di Santo, J. P. (2007) · Nature Reviews Immunology · doi:10.1038/nri2154 · Cited by 461
Self-citationThe E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A. M., Langdon, W. Y., Ikeda, F., Fededa, J. P., et al. (2014) · Nature · doi:10.1038/nature12998 · Cited by 456
Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., & Bartlett, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4405 · Cited by 440
Viaud, S., Terme, M., Flament, C., Taieb, J., André, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004942 · Cited by 437
Bachanova, V., Cooley, S., Defor, T. E., Verneris, M. R., Zhang, B., McKenna, D. H., Curtsinger, J., Panoskaltsis-Mortari, A., Lewis, D., Hippen, K., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532531 · Cited by 435
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Self-citationIannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., Zhang, B., Lenvik, A. J., Panoskaltsis-Mortari, A., Verneris, M. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2710 · Cited by 391
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
CIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 384
Self-citationEvaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants
Davies, S. M., Ruggieri, L., DeFor, T., Wagner, J. E., Weisdorf, D. J., Miller, J. S., Velardi, A., & Blazar, B. R. (2002) · Blood · doi:10.1182/blood-2002-04-1197 · Cited by 368
Fuchs, A., Cella, M., Giurisato, E., Shaw, A. S., & Colonna, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.3994 · Cited by 358
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bönig, H., Köhl, U., Kloess, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 348
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
Self-citationAlternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 341
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310
Self-citationBorg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.01.006 · Cited by 285
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. (2014) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 283
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Vey, N., Bourhis, J.-H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., et al. (2012) · Blood · doi:10.1182/blood-2012-06-437558 · Cited by 278
Sakamoto, N., Ishikawa, T., Kokura, S., Okayama, T., Oka, K., Ideno, M., Sakai, F., Kato, A., Tanabe, M., Enoki, T., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0632-8 · Cited by 270
Are natural killer cells superior CAR drivers?
Klingemann, H. (2014) · OncoImmunology · doi:10.4161/onci.28147 · Cited by 270
Mouse TIGIT inhibits NK‐cell cytotoxicity upon interaction with PVR
Stanietsky, N., Rovis, T. L., Glasner, A., Seidel, E., Tsukerman, P., Yamin, R., Enk, J., Jonjic, S., & Mandelboim, O. (2013) · European Journal of Immunology · doi:10.1002/eji.201243072 · Cited by 263
A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection
Deng, W., Gowen, B. G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T. L., Xiong, N., & Raulet, D. H. (2015) · Science · doi:10.1126/science.1258867 · Cited by 255
Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells
Marquardt, N., Béziat, V., Nyström, S., Hengst, J., Ivarsson, M. A., Kekäläinen, E., Johansson, H., Mjösberg, J., Westgren, M., Lankisch, T. O., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402756 · Cited by 254
Burns, L. J., Weisdorf, D. J., DeFor, T. E., Vesole, D. H., Repka, T. L., Blazar, B. R., Burger, S. R., Panoskaltsis-Mortari, A., Keever-Taylor, C. A., Zhang, M.-J., et al. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704086 · Cited by 252
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Mittal, D., Young, A., Stannard, K., Yong, M., Teng, M. W. L., Allard, B., Stagg, J., & Smyth, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0957 · Cited by 245
Self-citationBenson, D. M., Hofmeister, C. C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438028 · Cited by 244
Functional subsets of mouse natural killer cells
Hayakawa, Y., Huntington, N. D., Nutt, S. L., & Smyth, M. J. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00454.x · Cited by 244
Self-citationAdvantages and applications of CAR-expressing natural killer cells
Glienke, W., Esser, R., Priesner, C., Suerth, J. D., Schambach, A., Wels, W. S., Grez, M., Kloess, S., Arseniev, L., & Koehl, U. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00021 · Cited by 243
Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
Blake, S. J., Stannard, K., Liu, J., Allen, S., Yong, M. C. R., Mittal, D., Aguilera, A. R., Miles, J. J., Lutzky, V. P., de Andrade, L. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0944 · Cited by 243
Self-citationShah, N. N., Baird, K., Delbrook, C. P., Fleisher, T. A., Kohler, M. E., Rampertaap, S., Lemberg, K., Hurley, C. K., Kleiner, D. E., Merchant, M. S., et al. (2015) · Blood · doi:10.1182/blood-2014-07-592881 · Cited by 238
Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., & Miller, J. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0692 · Cited by 238
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
Tarek, N., Le Luduec, J.-B., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.-K. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 229
Bowles, J. A., Wang, S.-Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M.-A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-020057 · Cited by 227
Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12810 · Cited by 220
Role of Chemokines in the Biology of Natural Killer Cells
Maghazachi, A. A. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_20 · Cited by 216
Xu, L., Huang, Y., Tan, L., Yu, W., Chen, D., Lu, C., He, J., Wu, G., Liu, X., & Zhang, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.017 · Cited by 214
Benson, D. M., Bakan, C. E., Zhang, S., Collins, S. M., Liang, J., Srivastava, S., Hofmeister, C. C., Efebera, Y., Andre, P., Romagne, F., et al. (2011) · Blood · doi:10.1182/blood-2011-06-360255 · Cited by 208
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Becker, P. S. A., Suck, G., Nowakowska, P., Ullrich, E., Seifried, E., Bader, P., Tonn, T., & Seidl, C. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1792-y · Cited by 208
Improving the safety of cell therapy products by suicide gene transfer
Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00254 · Cited by 201
Sanmamed, M. F., Pastor, F., Rodriguez, A., Perez-Gracia, J. L., Rodriguez-Ruiz, M. E., Jure-Kunkel, M., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.014 · Cited by 190
Imamura, M., Shook, D., Kamiya, T., Shimasaki, N., Chai, S. M. H., Coustan-Smith, E., Imai, C., & Campana, D. (2014) · Blood · doi:10.1182/blood-2014-02-556837 · Cited by 188
Genßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I., Wagner, M., Steinbach, J. P., & Wels, W. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 187
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903225 · Cited by 180
Self-citationDelgado, D. C., Hank, J. A., Kolesar, J., Lorentzen, D., Gan, J., Seo, S., Kim, K., Shusterman, S., Gillies, S. D., Reisfeld, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2211 · Cited by 179
Stojanovic, A., Fiegler, N., Brunner-Weinzierl, M., & Cerwenka, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302091 · Cited by 175
Cutting Edge: Salivary Gland NK Cells Develop Independently of Nfil3 in Steady-State
Cortez, V. S., Fuchs, A., Cella, M., Gilfillan, S., & Colonna, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303469 · Cited by 173
Clinical utility of natural killer cells in cancer therapy and transplantation
Knorr, D. A., Bachanova, V., Verneris, M. R., & Miller, J. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.02.002 · Cited by 170
Lesokhin, A. M., Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010274 · Cited by 169
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
Gluck, W. L., Hurst, D., Yuen, A., Levine, A. M., Dayton, M. A., Gockerman, J. P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1087-3 · Cited by 166
Bi-specific Aptamers Mediating Tumor Cell Lysis
Boltz, A., Piater, B., Toleikis, L., Guenther, R., Kolmar, H., & Hock, B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.238261 · Cited by 165
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
Semeraro, M., Rusakiewicz, S., Minard‐Colin, V., Delahaye, N. F., Enot, D. P., Vely, F., Marabelle, A., Papoular, B., Pipéroglou, C., Ponzoni, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa2327 · Cited by 164
Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
Romee, R., Leong, J. W., & Fehniger, T. A. (2014) · Scientifica · doi:10.1155/2014/205796 · Cited by 164
Immunosurveillance and therapy of multiple myeloma are CD226 dependent
Guillerey, C., de Andrade, L. F., Vučković, S., Miles, K. M., Ngiow, S. F., Yong, M. C. R., Teng, M. W. L., Colonna, M., Ritchie, D. S., Chesi, M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77181 · Cited by 160
Self-citationBishara, A., Santis, D. D., Witt, C., Brautbar, C., Christiansen, F., Or, R., Nagler, A., & Slavin, S. (2004) · Tissue Antigens · doi:10.1111/j.0001-2815.2004.00182.x · Cited by 158
DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation
Martinet, L., de Andrade, L. F., Guillerey, C., Lee, J. S., Liu, J., Souza-Fonseca-Guimarães, F., Hutchinson, D. S., Kolesnik, T. B., Nicholson, S. E., Huntington, N. D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.006 · Cited by 157
Self-citationKim, P. S., Kwilas, A. R., Xu, W. V., Alter, S., Jeng, E. K., Wong, H. C., Schlom, J., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7470 · Cited by 156
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M. (1997) · Blood · doi:10.1182/blood.v89.6.2042 · Cited by 149
von Strandmann, E. P., Hansen, H. P., Reiners, K. S., Schnell, R., Borchmann, P., Merkert, S., Simhadri, V. R., Draube, A., Reiser, M., Purr, I., et al. (2005) · Blood · doi:10.1182/blood-2005-05-2177 · Cited by 147
CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance
Putz, E. M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.012 · Cited by 143
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde, N., Carlsten, M., Lee, M.-J., Minter, A., Tan, E. M., Kwok, M., Manasanch, E. E., Bhutani, M., Tageja, N., Roschewski, M. J., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.103085 · Cited by 137
The Helix-Loop-Helix Protein ID2 Governs NK Cell Fate by Tuning Their Sensitivity to Interleukin-15
Delconte, R. B., Shi, W., Sathe, P., Ushiki, T., Seillet, C., Minnich, M., Kolesnik, T. B., Rankin, L. C., Mielke, L. A., Zhang, J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.12.007 · Cited by 134
Self-citationGerdes, C. A., Nicolini, V., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0989 · Cited by 133
Baessler, T., Charton, J. E., Schmiedel, B. J., Grünebach, F., Krusch, M., Wacker, A., Rammensee, H., & Salih, H. R. (2009) · Blood · doi:10.1182/blood-2009-06-227934 · Cited by 130
Repression of GSK3 restores NK cell cytotoxicity in AML patients
Parameswaran, R., Ramakrishnan, P., Moreton, S. A., Xia, Z., Hou, Y., Lee, D. A., Gupta, K., Lima, M. J. G. D., Beck, R. C., & Wald, D. N. (2016) · Nature Communications · doi:10.1038/ncomms11154 · Cited by 121
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
IL-10 stimulatory effects on human NK cells explored by gene profile analysis
D, S. M. M., Panelli, M. C., Wang, E., Rossi, C. R., Pilati, P., Nitti, D., Lise, M., & Marincola, F. M. (2004) · Genes and Immunity · doi:10.1038/sj.gene.6364135 · Cited by 113
Schmohl, J., Gleason, M., Dougherty, P., Miller, J. S., & Vallera, D. A. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0391-8 · Cited by 112
NK Cells and Cancer Immunoediting
Guillerey, C., & Smyth, M. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_446 · Cited by 110
Self-citationRueff, J., Medinger, M., Heim, D. A., Passweg, J. R., & Stern, M. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.007 · Cited by 110
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Huang, B. Y., Zhan, Y. P., Zong, W. J., Yu, C. J., Li, J., Qu, Y. M., & Han, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134715 · Cited by 110
Tissue-resident natural killer cells and their potential diversity
Sojka, D. K., Tian, Z., & Yokoyama, W. M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.010 · Cited by 109
Nguyen, S., Béziat, V., Dhédin, N., Kuentz, M., Vernant, J., Debré, P., & Vieillard, V. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.380 · Cited by 105
The unconventional expression of IL‐15 and its role in NK cell homeostasis
Huntington, N. D. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.1 · Cited by 105
Self-citationChallenges of cancer therapy with natural killer cells
Klingemann, H. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.09.007 · Cited by 103
Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer
Bakema, J. E., & van Egmond, M. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_17 · Cited by 99
Bench to bedside: NK cells and control of metastasis
Krasnova, Y., Putz, E. M., Smyth, M. J., & Souza-Fonseca-Guimarães, F. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.10.001 · Cited by 97
Self-citationLundqvist, A., Yokoyama, H., Smith, A. L., Berg, M., & Childs, R. W. (2009) · Blood · doi:10.1182/blood-2008-11-190421 · Cited by 91
Steele, N. L., Anthony, A., Saunders, M. P., Esmarck, B., Ehrnrooth, E., Kristjansen, P. E. G., Nihlén, A., Hansen, L. T., & Cassidy, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.599 · Cited by 88
Rodríguez, J., Zárate, R., Bandrés, E., Boni, V., Hernandez, A. B., Sola, J. J., Honorato, B., Bitarte, N., & García‐Foncillas, J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.007 · Cited by 86
Schmiedel, B. J., Arélin, V., Grünebach, F., Krusch, M., Schmidt, S. M., & Salih, H. R. (2010) · International Journal of Cancer · doi:10.1002/ijc.25635 · Cited by 85
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
Wang, Z., Zhu, J., Gu, H., Yuan, Y., Zhang, B., Zhu, D., Zhou, J., Zhu, Y., & Chen, W. (2015) · Immunological Investigations · doi:10.3109/08820139.2015.1052145 · Cited by 84
Rossi, L. E., Avila, D. E., Spallanzani, R. G., Ziblat, A., Fuertes, M. B., Lapyckyj, L., Croci, D. O., Rabinovich, G. A., Domaica, C. I., & Zwirner, N. W. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0711339 · Cited by 84
Rationale for anti-CD137 cancer immunotherapy
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.026 · Cited by 84
Pérez‐Martínez, A., Fernández, L., Valentín, J., Martínez-Romera, I., Corral, M. D., Ramírez, M. R., Abad, L., Santamaría, S., González‐Vicent, M., Sirvent, S. I., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.07.011 · Cited by 80
Interleukin-15 in the treatment of cancer
Waldmann, T. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.973856 · Cited by 78
Positive and Negative Regulation by NK Cells in Cancer
Sungur, C. M., & Murphy, W. J. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014010805 · Cited by 71
Moga, E., Álvarez, E., Cantó, E., Vidal, S., Rodríguez-Sánchez, J. L., Sierra, J., & Briones, J. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.012 · Cited by 71
Melanoma Cells Inhibit NK Cell Functions—Letter
Sconocchia, G., Arriga, R., Tornillo, L., Terracciano, L., Ferrone, S., & Spagnoli, G. C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1181 · Cited by 70
Zhou, Q., Gil-Krzewska, A. J., Peruzzi, G., & Borrego, F. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12095 · Cited by 61
Roberti, M. P., Rocca, Y., Amat, M., Pampena, M. B., Loza, J., Coló, F. A., Fabiano, V. Y., Loza, C. M., Arriaga, J. M., Bianchini, M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2287-y · Cited by 58
Novel immune modulators used in hematology: impact on NK cells
Krieg, S., & Ullrich, E. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00388 · Cited by 55
Natural killer cell immunotherapy to target stem-like tumor cells
Grossenbacher, S. K., Canter, R. J., & Murphy, W. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0124-2 · Cited by 53
IL-10 Restricts Activation-Induced Death of NK Cells during Acute Murine Cytomegalovirus Infection
Stacey, M. A., Marsden, M., Wang, E. C. Y., Wilkinson, G. W. G., & Humphreys, I. R. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101021 · Cited by 51
Yang, R. K., Kalogriopoulos, N. A., Rakhmilevich, A. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1430-x · Cited by 50
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis
Guillerey, C., Chow, M. T., Miles, K. M., Olver, S. D., Sceneay, J., Takeda, K., Möller, A., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027468 · Cited by 46
Self-citationKellner, C., Hallack, D., Glorius, P., Staudinger, M., Nodehi, S. M., de Weers, M., van de Winkel, J. G. J., Parren, P. W. H. I., Stauch, M. B., Valerius, T., et al. (2011) · Leukemia · doi:10.1038/leu.2011.288 · Cited by 41
Wang, X., Ottosson, A., Ji, C., Feng, X., Nordenskjöld, M., Henter, J., Fadeel, B., & Zheng, C. (2009) · Haematologica · doi:10.3324/haematol.13783 · Cited by 36
Models to Study NK Cell Biology and Possible Clinical Application
Zamora, A. E., Grossenbacher, S. K., Aguilar, E. G., & Murphy, W. J. (2015) · Current Protocols in Immunology · doi:10.1002/0471142735.im1437s110 · Cited by 28
The Pathophysiological Role of Chemokines in the Regulation of NK Cell Tissue Homing
Bernardini, G., & Santoni, A. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014010386 · Cited by 14
Probing Human NK Cell Biology Using Human Immune System (HIS) Mice
Li, Y., & Santo, J. P. D. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_488 · Cited by 11
Cited by
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Jhunjhunwala, S., Hammer, C., & Delamarre, L. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00339-z · Cited by 1,490
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Metadata
- Authors
- Guillerey, C., Huntington, N. D., & Smyth, M. J.
- Venue
- Nature Immunology
- Published
- 2016-08-19
- Volume
- 17
- Issue
- 9
- Pages
- 1025-1036
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2515812752
- Cited by
- 1,066
- References
- 138
- FWCI
- 59.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.